Becker muscular dystrophy is an inherited muscle wasting diseases caused by a gene abnormality (mutation) that results in deficient or abnormal production of the dystrophin protein (dystrophinopathies). Becker muscular dystrophy follows x-linked recessive inheritance and is mostly found in males, but some females are also affected. Becker muscular dystrophy usually begins in the teens or early twenties and symptoms vary in affected individuals. Muscle deterioration progresses slowly but usually results in the need for a wheel chair. Muscles of the heart deteriorate (cardiomyopathy) in some affected individuals, and the process can become life-threatening. Symptoms of Becker muscular dystrophy usually begin in the teens or late twenties and initial symptoms may include cramping during exercise and reduced stamina during exercise. Muscle gradually deteriorates in the hips, pelvis, thighs and shoulders that can lead to walking on toes with the stomach forward. The progression of BMD is slower and more variable than Duchenne muscular dystrophy but usually results in the need for a wheel chair. The drug candidates for Becker muscular dystrophy pipeline include, but are not limited to Vamorolone, TG 5001 and AAV1-FS344.
Some of the companies having drugs in the becker muscular dystrophy pipeline include Milo Biotechnology LLC, PTC Therapeutics, Inc., Sarepta Therapeutics, Inc. and Sphaera Pharma Pvt. Ltd.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.